Phase angle as a prognostic factor of survival in patients with metastatic prostate cancer
Clinical Nutrition ESPEN · 2025
DOI: 10.1016/j.clnesp.2025.09.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Nutrition ESPEN, 2025. Verfasst von Tanya Cauz-Valero und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Urología, Instituto Nacional de Cancerología, Ciudad de México, México. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Instituto Nacional de Cancerología.
Abstract (Originalsprache)
BACKGROUND & AIMS: Phase angle (PA), derived from bioelectrical impedance analysis (BIA), is a non-invasive marker of cellular integrity and nutritional status. While its prognostic value has been demonstrated in various malignancies, evidence in metastatic prostate cancer (mPCa) is scarce. This study aimed to evaluate the association between PA and overall survival (OS) in patients with mPCa receiving androgen deprivation therapy (ADT). METHODS: We conducted a retrospective cohort study including 103 patients with confirmed mPCa undergoing ADT. PA was measured using multi-frequency BIA and patients were categorized into two groups: PA ≤ 4.0° and PA > 4.0°. Clinical, anthropometric, and body composition data were collected. OS was estimated using Kaplan-Meier analysis, and Cox proportional hazards models were used to assess the association between PA and mortality. RESULTS: Patients with PA ≤ 4.0° (n = 24; 23.3 %) had significantly lower fat-free mass and higher fat mass percentage compared to those with PA > 4.0° (n = 79; 76.7 %). A significantly higher proportion of patients with PA ≤ 4.0° experienced disease progression (79.2 % vs. 45.6 %, p = 0.004). Kaplan-Meier analysis showed reduced survival in the low PA group (Log-rank p = 0.0043). In multivariate Cox regression, PA ≤ 4.0° was independently associated with higher mortality risk (HR: 4.603; 95 % CI: 1.653-12.817; p = 0.003). CONCLUSIONS: Low phase angle is independently associated with reduced survival in men with mPCa undergoing ADT. PA may serve as a reliable, low-cost biomarker for risk stratification and nutritional assessment in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Urología, Instituto Nacional de Cancerología, Ciudad de México, México.
- Departamento de Epidemiología, Instituto Nacional de Cancerología, Ciudad de México, México.
- Departamento de Nutrición Oncológica, Instituto Nacional de Cancerología, Ciudad de México, México.
- Departamento de Urología, Instituto Nacional de Cancerología, Ciudad de México, México. Electronic address: incanurologia@gmail.com.
Förderung
- Instituto Nacional de Cancerología
Zitieren
APA
Cauz-Valero, T., Herrera-López, E. E., Scavuzzo, A., Calvo-Vázquez, I., Ramírez-González, A., Hurtado-Vázquez, A., Reynoso-Noverón, N., Pérez-Camargo, D. A., & Jímenez-Ríos, M. Á. (2025). Phase angle as a prognostic factor of survival in patients with metastatic prostate cancer. Clinical Nutrition ESPEN. https://doi.org/10.1016/j.clnesp.2025.09.028
Vancouver
Cauz-Valero T, Herrera-López EE, Scavuzzo A, Calvo-Vázquez I, Ramírez-González A, Hurtado-Vázquez A, et al. Phase angle as a prognostic factor of survival in patients with metastatic prostate cancer. Clinical Nutrition ESPEN. 2025. doi:10.1016/j.clnesp.2025.09.028
BibTeX
@article{CauzValero2025,
author = {Cauz-Valero, Tanya and Herrera-López, Ema Elvira and Scavuzzo, Anna and Calvo-Vázquez, Ivan and Ramírez-González, Andrey and Hurtado-Vázquez, Alonso and Reynoso-Noverón, Nancy and Pérez-Camargo, Dana Aline and Jímenez-Ríos, Miguel Ángel},
title = {Phase angle as a prognostic factor of survival in patients with metastatic prostate cancer},
journal = {Clinical Nutrition ESPEN},
year = {2025},
doi = {10.1016/j.clnesp.2025.09.028}
}
EUVIMED